Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection
Maria João Baptista(Josep Carreras Leukaemia Research Institute), José‐Tomás Navarro(Universitat Autònoma de Barcelona), José Luís Mate(Universitat Autònoma de Barcelona), Eva González‐Barca(Institut Català d'Oncologia), Ferran Vall‐Llovera(Mútua Terrassa), María José Terol(Hospital Clínico Universitario de Valencia), Gustavo Tapia(Hospital Universitari Germans Trias i Pujol), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Josep‐María Ribera(Universitat Autònoma de Barcelona), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda), Ana M Muñoz‐Mármol(Universitat Autònoma de Barcelona), Pilar Miralles(Hospital General Universitario Gregorio Marañón), Miriam Moreno(Universitat Autònoma de Barcelona), Josep Muncunill(Universitat Autònoma de Barcelona), Olga García(Universitat Autònoma de Barcelona), Evarist Feliú(Universitat Autònoma de Barcelona)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Non-coding recurrent mutations in chronic lymphocytic leukaemia
|Nature|2015|851